Characteristics of COVID-19 in patients with multiple sclerosis.
COVID-19
Iran
Multiple sclerosis
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
06
09
2021
revised:
11
11
2021
accepted:
27
11
2021
pubmed:
14
12
2021
medline:
17
2
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population. Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe. A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003-5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41-6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms. The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity.
Sections du résumé
BACKGROUND
BACKGROUND
Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population.
METHODS
METHODS
Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe.
RESULTS
RESULTS
A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003-5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41-6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms.
CONCLUSION
CONCLUSIONS
The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity.
Identifiants
pubmed: 34896875
pii: S2211-0348(21)00703-3
doi: 10.1016/j.msard.2021.103437
pmc: PMC8629769
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
103437Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Curr Nutr Rep. 2021 Sep;10(3):200-210
pubmed: 33948913
Mult Scler Relat Disord. 2021 May;50:102798
pubmed: 33571791
Eur J Neurol. 2021 Nov;28(11):3712-3721
pubmed: 34152073
Mult Scler Relat Disord. 2021 Sep;54:103104
pubmed: 34216998
mSystems. 2021 May 4;6(3):
pubmed: 33947804
BMC Neurol. 2020 May 2;20(1):169
pubmed: 32359352
Mult Scler. 2018 Feb;24(2):92-95
pubmed: 29451442
Public Health. 2019 Oct;175:138-144
pubmed: 31476710
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Front Immunol. 2020 Dec 01;11:576818
pubmed: 33335527
Mult Scler Relat Disord. 2021 May;50:102800
pubmed: 33578206
Mult Scler Relat Disord. 2021 May;50:102856
pubmed: 33662858
Infect Genet Evol. 2021 Jan;87:104647
pubmed: 33264669
J Neurol. 2020 Dec;267(12):3467-3475
pubmed: 32638107
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):841-846
pubmed: 32614810
Mult Scler Relat Disord. 2020 Nov;46:102472
pubmed: 32890817
PLoS One. 2019 Apr 9;14(4):e0214738
pubmed: 30964886
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885
Mult Scler Relat Disord. 2020 Jun;41:102135
pubmed: 32339915
Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744
pubmed: 34240579
Mult Scler Relat Disord. 2019 Aug;33:158-161
pubmed: 31203146
PLoS One. 2021 Oct 5;16(10):e0258095
pubmed: 34610034
Mult Scler Relat Disord. 2020 Nov;46:102540
pubmed: 33032060
J Neurol Sci. 2021 Jan 15;420:117230
pubmed: 33256952
Basic Clin Neurosci. 2020 Mar-Apr;11(2):201-206
pubmed: 32855779
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Mult Scler Relat Disord. 2020 Aug;43:102195
pubmed: 32460086
Mult Scler Relat Disord. 2020 Jul;42:102185
pubmed: 32408147
JAMA Neurol. 2020 Feb 1;77(2):184-191
pubmed: 31589278
Mult Scler Relat Disord. 2020 Jul;42:102120
pubmed: 32315980